UFP (UFPT) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 04, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-12648
Entity Registrant Name	UFP Technologies, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2314970
Entity Address, Address Line One	100 Hale Street
Entity Address, City or Town	Newburyport
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01950
City Area Code	978
Local Phone Number	352-2200
Title of 12(b) Security	Common Stock
Trading Symbol	UFPT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		7,674,363
Entity Central Index Key	0000914156
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 16,356	$ 5,263
Receivables, net	89,151	64,449
Inventories	88,690	70,191
Prepaid expenses and other current assets	4,558	3,433
Refundable income taxes	2,252	1,297
Total current assets	201,007	144,633
Property, plant and equipment, net	70,311	62,137
Goodwill	204,732	113,263
Intangible assets, net	134,718	64,116
Non-qualified deferred compensation plan	6,162	5,323
Right of use assets	15,447	13,588
Deferred income taxes	72	607
Equity method investment	5,623	0
Other assets	436	469
Total assets	638,508	404,136
Current liabilities:
Accounts payable	26,268	22,286
Accrued expenses	29,649	22,085
Deferred revenue	5,798	6,616
Lease liabilities	3,979	3,222
Income taxes payable	153	0
Current portion of long-term debt	12,500	4,000
Total current liabilities	78,347	58,209
Long-term debt, excluding current installments	199,500	28,000
Deferred income taxes	2,441	428
Non-qualified deferred compensation plan	6,169	5,412
Lease liabilities	11,961	10,815
Other liabilities	10,944	15,181
Total liabilities	309,362	118,045
Commitments and Contingencies
us-gaap_StockholdersEquityAbstract
Preferred stock, $.01 par value, 1,000,000 shares authorized; no shares issued	0	0
Common stock, $.01 par value, 20,000,000 shares authorized; 7,703,922 and 7,674,363 shares issued and outstanding, respectively, at June 30, 2024; 7,669,339 and 7,639,780 shares issued and outstanding, respectively, at December 31, 2023	77	76
Additional paid-in capital	38,957	38,814
Retained earnings	290,126	247,520
Accumulated other comprehensive (loss) income	573	268
Treasury stock at cost, 29,559 shares at June 30, 2024 and 29,559 shares at December 31, 2023	(587)	(587)
Total stockholders’ equity	329,146	286,091
Total liabilities and stockholders' equity	$ 638,508	$ 404,136

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	7,703,922	7,669,339
Common stock, shares outstanding (in shares)	7,674,363	7,639,780
Treasury Stock, Common, Shares (in shares)	29,559	29,559

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net sales	$ 145,165	$ 100,784	$ 360,351	$ 298,575
Cost of sales	103,642	73,034	255,714	212,479
Gross profit	41,523	27,750	104,637	86,096
Selling, general & administrative expenses	15,789	12,467	43,601	37,771
Acquisition costs	732	0	1,676	0
Change in fair value of contingent consideration	238	238	714	3,289
(Gain) loss on sale of property, plant & equipment	0	0	7	108
Operating income	24,764	15,045	58,639	44,928
Interest expense, net	3,475	933	4,683	2,890
Other expenses (income)	70	(29)	30	28
Income before income tax expense	21,219	14,141	53,926	42,010
Income tax expense	4,858	2,447	11,320	8,694
Net income	$ 16,361	$ 11,694	$ 42,606	$ 33,316
Net income per share:
Basic (in dollars per share)	$ 2.13	$ 1.53	$ 5.56	$ 4.37
Diluted (in dollars per share)	$ 2.11	$ 1.52	$ 5.49	$ 4.33
Weighted average common shares outstanding:
Basic (in shares)	7,674	7,639	7,666	7,619
Diluted (in shares)	7,772	7,709	7,763	7,697
Comprehensive Income
Net income	$ 16,361	$ 11,694	$ 42,606	$ 33,316
Other comprehensive income:
Foreign currency translation adjustment	1,070	(793)	306	(259)
Other comprehensive gain (loss)	1,070	(793)	306	(259)
Comprehensive income	$ 17,431	$ 10,901	$ 42,912	$ 33,057

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock Outstanding [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Dec. 31, 2022	7,582				30
Balance at Dec. 31, 2022	$ 76	$ 36,070	$ 202,596	$ (610)	$ (587)	$ 237,545
Share-based compensation (in shares)	49				0
Share-based compensation	$ 0	1,056	0	0	$ 0	1,056
Exercise of stock options (in shares)	3				0
Exercise of stock options	$ 0	0	0	0	$ 0	0
Net share settlement of restricted stock units (in shares)	(21)				0
Net share settlement of restricted stock units	$ 0	(2,413)	0	0	$ 0	(2,413)
Other comprehensive income	$ 0	0	0	493		493
Net income		0	9,739		$ 0	9,739
Balance (in shares) at Mar. 31, 2023	7,613				30
Balance at Mar. 31, 2023	$ 76	34,777	212,335	(117)	$ (587)	246,484
Issuance of common stock (in shares)	0				0
Issuance of common stock	$ 0	64	0	0	$ 0	64
Balance (in shares) at Dec. 31, 2022	7,582				30
Balance at Dec. 31, 2022	$ 76	36,070	202,596	(610)	$ (587)	237,545
Other comprehensive income						(259)
Net income						33,316
Balance (in shares) at Sep. 30, 2023	7,639				30
Balance at Sep. 30, 2023	$ 76	37,851	235,912	(869)	$ (587)	272,383
Balance (in shares) at Mar. 31, 2023	7,613				30
Balance at Mar. 31, 2023	$ 76	34,777	212,335	(117)	$ (587)	246,484
Share-based compensation (in shares)	4				0
Share-based compensation	$ 0	1,197	0	0	$ 0	1,197
Exercise of stock options (in shares)	22				0
Exercise of stock options	$ 0	680	0	0	$ 0	680
Other comprehensive income	0	0	0	41	0	41
Net income	$ 0	0	11,883	0	$ 0	11,883
Balance (in shares) at Jun. 30, 2023	7,639				30
Balance at Jun. 30, 2023	$ 76	36,654	224,218	(76)	$ (587)	260,285
Share-based compensation (in shares)	0				0
Share-based compensation	$ 0	1,197	0	0	$ 0	1,197
Other comprehensive income	0	0	0	(793)	0	(793)
Net income	$ 0	0	11,694	0	$ 0	11,694
Balance (in shares) at Sep. 30, 2023	7,639				30
Balance at Sep. 30, 2023	$ 76	37,851	235,912	(869)	$ (587)	272,383
Balance (in shares) at Dec. 31, 2023	7,640				30
Balance at Dec. 31, 2023	$ 76	38,814	247,520	268	$ (587)	286,091
Share-based compensation (in shares)	48				0
Share-based compensation	$ 1	1,512	0	0	$ 0	1,513
Exercise of stock options (in shares)	4				0
Exercise of stock options	$ 0	54	0	0	$ 0	54
Net share settlement of restricted stock units (in shares)	(22)				0
Net share settlement of restricted stock units	$ 0	(4,751)	0	0	$ 0	(4,751)
Other comprehensive income	$ 0	0	0	(584)	0	(584)
Net income		0	12,693	0	$ 0	12,693
Balance (in shares) at Mar. 31, 2024	7,670				30
Balance at Mar. 31, 2024	$ 77	35,629	260,213	(316)	$ (587)	295,016
Balance (in shares) at Dec. 31, 2023	7,640				30
Balance at Dec. 31, 2023	$ 76	38,814	247,520	268	$ (587)	286,091
Other comprehensive income						306
Net income						42,606
Balance (in shares) at Sep. 30, 2024	7,674				30
Balance at Sep. 30, 2024	$ 77	38,957	290,126	573	$ (587)	329,146
Balance (in shares) at Mar. 31, 2024	7,670				30
Balance at Mar. 31, 2024	$ 77	35,629	260,213	(316)	$ (587)	295,016
Share-based compensation (in shares)	2				0
Share-based compensation	$ 0	1,736	0	0	$ 0	1,736
Exercise of stock options (in shares)	2				0
Exercise of stock options	$ 0	53	0	0	$ 0	53
Other comprehensive income	$ 0	0	0	(181)	0	(181)
Net income		0	13,552	0	$ 0
Balance (in shares) at Jun. 30, 2024	7,674				30
Balance at Jun. 30, 2024	$ 77	37,418	273,765	(497)	$ (587)	310,176
Share-based compensation (in shares)	0				0
Share-based compensation	$ 0	1,539	0	0	$ 0	1,539
Other comprehensive income	0	0	0	1,070	0	1,070
Net income	$ 0	0	16,361	0	$ 0	16,361
Balance (in shares) at Sep. 30, 2024	7,674				30
Balance at Sep. 30, 2024	$ 77	$ 38,957	$ 290,126	$ 573	$ (587)	$ 329,146

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Net income	$ 42,606	$ 33,316
Adjustments to reconcile net income to net cash provided byoperating activities:
Depreciation and amortization	10,058	8,446
Loss on disposal of property, plant & equipment	7	108
Share-based compensation	4,787	3,450
Deferred income taxes	827	474
Change in fair value of contingent consideration	714	3,289
Changes in operating assets and liabilities:
Receivables, net	(2,893)	(5,791)
Inventories	(5,633)	(16,267)
Prepaid expenses and other current assets	(940)	377
Other assets	(490)	1,255
Accounts payable	736	6,715
Accrued expenses	(622)	(4,272)
Deferred revenue	(819)	(865)
Income taxes payable	(753)	(2,161)
Non-qualified deferred compensation plan and other liabilities	(5,416)	559
Net cash provided by operating activities	42,169	28,633
Cash flows from investing activities:
Acquisition of Marble Medical, net of cash acquired	(196,432)	0
Purchase of real estate	(3,214)	0
Additions to property, plant, and equipment	(6,649)	(7,734)
Proceeds from sale of fixed assets	15	2
Net cash used in investing activities	(206,280)	(7,732)
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract
Proceeds from advances on revolving line of credit	115,200	9,000
Payments on revolving line of credit	(28,200)	(18,000)
Proceeds from borrowings of long-term debt	125,000	0
Principal payments of long-term debt	(32,000)	(3,000)
Payment of contingent consideration	(188)	(5,000)
Principal payments on finance lease obligations	(58)	(47)
Proceeds from the exercise of stock options	107	680
Payment of statutory withholdings for restricted stock units vested	(4,751)	(2,413)
Net cash used in financing activities	175,110	(18,780)
Effect of foreign currency exchange rates on cash and cash equivalents	94	(196)
Net increase in cash and cash equivalents	11,093	1,925
Cash and cash equivalents at beginning of period	5,263	4,451
Cash and cash equivalents at end of period	$ 16,356	$ 6,376

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	(1) Basis of Presentation The interim condensed consolidated financial statements of UFP Technologies, Inc. (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10-Q and do not include all the information and note disclosures required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023, included in the Company's 2023 Annual Report on Form 10-K, as filed with the Securities and Exchange Commission. The condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, the condensed consolidated statements of comprehensive income for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 are unaudited but, in the opinion of management, include all adjustments (consisting of normal, recurring adjustments) necessary for a fair presentation of results for these interim periods. The condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company’s annual financial statements that were audited by an independent registered public accounting firm but does not include all of the information and footnotes required for complete annual financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three- and nine-month periods ended September 30, 2024 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2024. Recent Accounting Pronouncements There are no newly issued accounting pronouncements that the Company expects to have a material effect on the financial statements.

Note 2 - Acquisition

Note 2 - Acquisition	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Business Combination Disclosure [Text Block]	(2) Acquisitions Marble Medical On June 24, 2024, the Company purchased 100% of the outstanding shares of common stock of Marble Medical, Inc., (“Marble”) pursuant to a stock purchase agreement and related agreements, for an aggregate purchase price of $4.5 million in cash, plus up to an additional $0.5 million based upon the achievement of sales targets of Marble for each of the 12-month periods ended December 31, 2024, and 2025. As of the opening balance sheet the contingent consideration had a fair value of approximately $400 thousand. The purchase price was subject to an adjustment based upon Marble’s estimated working capital at closing, which resulted in an increase of approximately $100 thousand and is subject to further adjustment when the final working capital is determined. A portion of the purchase price is being held by the Company to indemnify the Company against certain claims, losses, and liabilities. The Purchase Agreement contains customary representations, warranties, and covenants customary for transactions of this type. Founded in 1988 and headquartered in Tallahassee, FL, Marble develops and manufactures adhesive based medical components and single-use devices. The purchase price includes certain real estate, which encompasses Marble’s manufacturing, warehouse and office facilities. Marble brings to the Company adhesives expertise as well as precision die cutting capabilities. The following table summarizes the allocation of the total purchase price of approximately $5.0 million, net of cash acquired, to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s preliminary estimates of fair value (in thousands): Purchase Price Allocation Cash $ 815 Accounts receivable 872 Inventory 494 Other current assets 24 Property, plant, and equipment 1,018 Customer contracts & relationships 250 Intellectual property 300 Non-compete agreement 50 Goodwill 2,564 Total assets acquired 6,387 Accounts payable (41 ) Accrued expenses (519 ) Total liabilities assumed (560 ) Total assets acquired, net of liabilities assumed 5,827 Less: cash acquired (815 ) Purchase price, net of cash acquired $ 5,012 Acquisition costs associated with the transaction of approximately $146 thousand were charged to expense during the nine months ended September 30, 2024. These costs were primarily for legal services and are reflected on the face of the condensed consolidated statement of comprehensive income. The amount of revenue and pre-tax income of Marble recognized since the acquisition date, which is included in the condensed consolidated statement of comprehensive income for the nine months ended September 30, 2024, was approximately $2.0 million and $0.3 million, respectively. 100% of the goodwill related to the Marble acquisition is expected to be deductible for tax purposes. AJR Enterprises On July 1, 2024, the Company purchased 100% of the issued and outstanding membership interests of AJR Enterprises, LLC, (“AJR”) pursuant to a securities purchase agreement and related agreements, for an aggregate purchase price of $110 million in cash. The purchase price was subject to an adjustment based upon AJR’s estimated working capital at closing, which resulted in a increase of approximately $500 thousand and is subject to further adjustment when the final working capital is determined. A portion of the purchase price is being held by the Company to indemnify the Company against certain claims, losses, and liabilities. The Purchase Agreement contains customary representations, warranties, and covenants customary for transactions of this type. Founded in 1997 and headquartered in St. Charles, IL, with an additional manufacturing plant in Santiago, Dominican Republic, AJR develops and manufactures single-use patient handling systems. Patient surfaces and transfer devices are a growing market due in part to government guidelines and legislation around safe patient handling. AJR’s ‘cut and sew’ manufacturing capabilities and specialty fabrics expertise supplement the Company’s thermoplastic joining expertise, allowing the Company to offer a comprehensive suite of development, commercialization, and manufacturing services for this market. The following table summarizes the allocation of the total purchase price of approximately $110.5 million, net of cash acquired, to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s preliminary estimates of fair value (in thousands): Purchase Price Allocation Cash $ 3,000 Accounts receivable 17,138 Inventory 9,229 Other current assets 210 Property, plant, and equipment 1,149 Customer contracts & relationships 40,389 Intellectual property 8,245 Non-compete agreement 661 Lease right of use assets 2,024 Goodwill 41,710 Total assets acquired 123,755 Accounts payable (1,103 ) Accrued expenses (7,092 ) Lease liabilities (2,024 ) Total liabilities assumed (10,219 ) Total assets acquired, net of liabilities assumed 113,536 Less: cash acquired (3,000 ) Purchase price, net of cash acquired $ 110,536 Acquisition costs associated with the transaction were approximately $589 thousand charged to expense during the nine months ended September 30, 2024. These costs were primarily for legal, due diligence, and valuation services, and are reflected on the face of the condensed consolidated statement of comprehensive income. The amount of revenue and pre-tax income of AJR recognized since the acquisition date, which is included in the condensed consolidated statement of comprehensive income for the nine months ended September 30, 2024, was approximately $27.7 million and $5.7 million, respectively. 100% of the goodwill related to the AJR acquisition is expected to be deductible for tax purposes. Welch Fluorocarbon On July 15, 2024, the Company purchased 100% of the outstanding shares of common stock of Welch Fluorocarbon, Inc., (“Welch”) pursuant to a stock purchase agreement and related agreements, for an aggregate purchase price of $34.6 million in cash, plus up to an additional $6.0 million based upon the achievement of certain EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization) targets of Welch for each of the 12-month periods ended December 31, 2024, 2025, and 2026. The contingent consideration has a fair value of approximately $800 thousand as of the opening balance sheet. The purchase price was subject to an adjustment based upon Welch’s working capital at closing which resulted in a decrease of approximately $200 thousand. A portion of the purchase price is being held by the Company to indemnify the Company against certain claims, losses, and liabilities. The Purchase Agreement contains customary representations, warranties, and covenants customary for transactions of this type. Founded in 1985 and headquartered in Dover, NH, Welch develops and manufactures thermoformed, and heat sealed implantable medical device components utilizing thin, high-performance films. Welch brings thin film thermoforming capabilities and expertise in developing and manufacturing components for implantable medical devices. Also on July 15, 2024, pursuant to separate purchase and sale agreements (with separate legal parties), the Company purchased certain real estate in Dover, NH, which encompasses a majority of Welch’s manufacturing, warehousing and office facilities for an aggregate purchase of approximately $3.2 million. The following table summarizes the allocation of the total purchase price of approximately $35.2 million, net of cash acquired, to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s preliminary estimates of fair value (in thousands): Purchase Price Allocation Cash $ 3,817 Accounts receivable 1,506 Inventory 1,969 Other current assets 115 Property, plant, and equipment 824 Customer contracts & relationships 3,697 Intellectual property 7,859 Non-compete agreement 176 Lease right of use assets 150 Goodwill 19,367 Total assets acquired 39,480 Accounts payable (215 ) Accrued expenses (77 ) Lease liabilities (150 ) Total liabilities assumed (442 ) Total assets acquired, net of liabilities assumed 39,038 Less: cash acquired (3,817 ) Net assets acquired, net of cash acquired $ 35,221 Acquisition costs associated with the transaction were approximately $271 thousand charged to expense during the nine months ended September 30, 2024. These costs were primarily for legal and valuation services and are reflected on the face of the condensed consolidated statement of comprehensive income. The amount of revenue and pre-tax income of Welch recognized since the acquisition date, which is included in the condensed consolidated statement of comprehensive income for the nine months ended September 30, 2024, was approximately $3.2 million and $0.2 million, respectively. 100% of the goodwill related to the Welch acquisition is expected to be deductible for tax purposes. AQF On August 23, 2024, the Company purchased 100% of the issued and outstanding membership interests of the parent holding companies of AQF Limited, operating as AQF Medical, (“AQF”) pursuant to a share purchase agreement and related agreements, for an aggregate purchase price of €43 million in cash (total purchase price in U.S. Dollars amounted to approximately $47.8 million). The purchase price was subject to an adjustment based upon AQF’s working capital at closing and the assumption of certain liabilities, which resulted in a decrease of approximately $900 thousand. A portion of the purchase price is being held by the Company to indemnify the Company against certain claims, losses, and liabilities. The Purchase Agreement contains customary representations, warranties, and covenants customary for transactions of this type. Founded in 2005 and headquartered in Navan, Ireland with additional joint venture operations in Singapore, AQF develops and manufactures custom-engineered foam and thermoplastic components used in a wide range of medical devices and packaging. AQF brings to the Company additional expertise in converting specialty foams and films, an expanded European manufacturing presence, and an Asian market presence in Singapore. The following table summarizes the allocation of the total purchase price of approximately $46.9 million, net of cash acquired, to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s preliminary estimates of fair value (in thousands): Purchase Price Allocation Cash $ 3,381 Accounts receivable 2,237 Inventory 1,150 Other current assets 204 Property, plant, and equipment 976 Customer contracts & relationships 10,363 Intellectual property 2,343 Non-compete agreement 395 Lease right of use assets 1,723 Equity Method Investment 5,623 Goodwill 27,651 Total assets acquired 56,046 Accounts payable (1,890 ) Accrued expenses (487 ) Deferred taxes (1,711 ) Lease liabilities (1,723 ) Total liabilities assumed (5,811 ) Total assets acquired, net of liabilities assumed 50,235 Less: cash acquired (3,381 ) Purchase price, net of cash acquired $ 46,854 Acquisition costs associated with the transaction were approximately $639 thousand charged to expense during the nine months ended September 30, 2024. These costs were primarily for legal, due diligence, and valuation services and are reflected on the face of the condensed consolidated statement of comprehensive income. The amount of revenue and pre-tax income of AQF recognized since the acquisition date, which is included in the condensed consolidated statement of comprehensive income for the three and nine months ended September 30, 2024,was approximately $2.1 million and $0.5 million, respectively. None of the goodwill related to the AQF acquisition is expected to be deductible for tax purposes. Pro-forma statements The following table contains an unaudited pro forma condensed consolidated statement of operations for the three- and nine-month periods ended September 30, 2024 and 2023, as if the Marble and AJR acquisitions had occurred at the beginning of the nine-month periods and as if the Welch and AQF acquisitions had occurred at the beginning of the three- and nine-month periods (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Sales $ 148,515 $ 128,136 $ 435,494 $ 378,105 Operating Income $ 25,039 $ 17,648 $ 70,567 $ 55,430 Net Income $ 16,433 $ 11,697 $ 47,495 $ 35,492 Earnings per share: Basic $ 2.14 $ 1.53 $ 6.20 $ 4.66 Diluted $ 2.11 $ 1.52 $ 6.12 $ 4.61 The above unaudited pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have occurred had both acquisitions occurred as presented. In addition, future results may vary significantly from the results reflected in such pro forma information.

Note 3 - Equity Method Investme

Note 3 - Equity Method Investment	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	(3) Equity Method Investment In conjunction with the acquisition of AQF, the Company became 50% owners of the equity interest in AQF Asia PTE Ltd., located in Singapore (“AQF Asia”). While the Company owns 50% of the equity interest of AQF Asia and does have significant influence over the entity, the Company has concluded that it does not have control of AQF Asia due to certain “veto rights” held by the “other” joint venture partner with regards to management decision making. As a result, the Company accounts for its ownership interest in AQF Asia following the equity method of accounting, in accordance with ASC 323, Investments —Equity Method and Joint Ventures. Under this method, the carrying cost is initially recorded at fair value and then increased or decreased by recording its percentage of gain or loss in the condensed consolidated statement of comprehensive income and a corresponding change to the carrying value of the asset. The initial fair value of this equity method investment was approximately $5.6 million. The Company’s 50% share of AQF Asia’s net earnings during the third quarter of 2024 was not material.

Note 4 - Revenue Recognition

Note 4 - Revenue Recognition	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	(4) Revenue Recognition The Company recognizes revenue when a customer obtains control of a promised good or service. The amount of revenue recognized reflects the consideration that the Company expects to be entitled to in exchange for promised goods or services. The Company recognizes revenue in accordance with the core principles of ASC 606 which include (1) identifying the contract with a customer, (2) identifying separate performance obligations within the contract, (3) determining the transaction price, (4) allocating the transaction price to the performance obligations, and (5) recognizing revenue. The Company recognizes all but an immaterial portion of its product sales upon shipment. The Company recognizes revenue from the sale of tooling and machinery primarily upon customer acceptance. The Company recognizes revenue from engineering services, which are primarily product development services, as the services are performed or as otherwise determined based on the substance of the agreement. The Company recognizes revenue from bill-and-hold transactions at the time the specified goods are complete and available to the customer. Standard payment terms are net 30 days unless contract terms state otherwise. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or after performance, resulting in a significant financing component. We do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. In the ordinary course of business, the Company accepts sales returns from customers for defective goods, such amounts being immaterial. Although only applicable to an insignificant number of transactions, the Company has elected to exclude sales taxes from the transaction price. The Company has elected to account for shipping and handling activities for which the Company is responsible under the terms and conditions of the sale not as performance obligations but rather as fulfillment costs. These activities are required to fulfill the Company’s promise to transfer the goods and are expensed when revenue is recognized. Variable consideration to be included in the transaction price is estimated using either the expected value method or the most likely method based on facts and circumstances. Variable consideration is included in the transaction price if it is probable that a significant future reversal of cumulative revenue under the contract will not occur. The Company has elected to not disclose the aggregate amount of the transaction price allocated to unsatisfied performance obligations, as the Company’s contracts have an original expected duration of one year or less, or revenue has been recognized at the amount for which the Company has the right to invoice for engineering services performed. Disaggregated Revenue The following table presents the Company’s revenue disaggregated by the major types of goods and services sold to the Company’s customers (in thousands) (See Note 13 for further information regarding net sales by market): Three Months Ended Nine Months Ended September 30, September 30, Net sales of: 2024 2023 2024 2023 Products $ 142,877 $ 98,261 $ 351,395 $ 291,612 Tooling and Machinery 1,420 1,431 5,977 2,985 Engineering services 868 1,092 2,979 3,978 Total net sales $ 145,165 $ 100,784 $ 360,351 $ 298,575 Contract balances The timing of revenue recognition may differ from the timing of invoicing to customers. When invoicing occurs prior to revenue recognition, the Company has contract liabilities included within “deferred revenue” on the condensed consolidated balance sheets. The following table presents a roll-forward of contract liabilities activity for the nine-month periods ended September 30, 2024 and 2023 (in thousands): Contract Liabilities Nine Months Ended 2024 2023 Deferred revenue - beginning of period $ 6,616 $ 4,679 Deferred revenue acquired in Welch Fluorocarbon acquisition 8 - Increases due to consideration received from customers 3,302 3,169 Revenue recognized (4,128 ) (4,034 ) Deferred revenue - end of period $ 5,798 $ 3,814 Revenue recognized during the nine-month periods ended September 30, 2024 and 2023 from amounts included in deferred revenue at the beginning of the period were approximately $3.4 million and $2.4 million, respectively. When invoicing occurs after revenue recognition, the Company has contract assets, included within “receivables, net” on the condensed consolidated balance sheets. The following table presents opening and closing balances of contract assets for the nine-month periods ended September 30, 2024 and 2023 (in thousands): Contract Assets Nine Months Ended 2024 2023 Unbilled Receivables - beginning of period $ 114 $ 270 Increases due to revenue recognized, not invoiced to customers 1,620 2,898 Decreases due to customer invoicing (1,532 ) (3,020 ) Unbilled Receivables - end of period $ 202 $ 148

Note 5 - Supplemental Cash Flow

Note 5 - Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	(5) Supplemental Cash Flow Information Supplemental cash flow information consists of the following (in thousands): Nine Months Ended September 30, 2024 2023 Cash paid for: Interest $ 4,427 $ 2,838 Income taxes, net of refunds $ 9,505 $ 10,174 Non-cash investing and financing activities: Capital additions accrued but not yet paid $ 158 $ 185 Operating lease right of use assets $ 4,043 $ 2,492 Operating lease liabilities $ (4,056 ) $ (2,548 ) Financing lease right of use assets $ 35 $ - Financing lease liablities $ (58 ) $ -

Note 6 - Receivables and Allowa

Note 6 - Receivables and Allowance for Credit Losses	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	(6) Receivables and Allowance for Credit Losses Receivables consist of the following (in thousands): September 30, December 31, December 31, 2024 2023 2022 Accounts receivable–trade $ 90,205 $ 65,176 $ 55,850 Less allowance for credit losses (1,054 ) (727 ) (733 ) Receivables, net $ 89,151 $ 64,449 $ 55,117 The Company is exposed to credit losses primarily through sales of products and services. The Company’s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the status of customers' trade accounts receivable. Due to the short-term nature of such receivables, the estimate of the amount of accounts receivable that may not be collected is based on the aging of the accounts receivable balances and the financial condition of customers. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. The Company’s monitoring activities include timely account reconciliation, dispute resolution, payment confirmation, consideration of customers' financial condition and macroeconomic conditions. Balances are written-off when determined to be uncollectible. Estimates based on an assessment of anticipated payment and all other historical, current, and future information that is reasonably available are used to determine the allowance. The following table provides a roll-forward of the allowance for credit losses that is deducted from accounts receivable to present the net amount expected to be collected for the nine months ended September 30, 2024 and 2023 (in thousands): Allowance for Credit Nine Months Ended 2024 2023 Allowance - beginning of period $ 727 $ 733 Adjustment for expected credit losses 355 (5 ) Amounts written off against the allowance (28 ) (11 ) Recoveries - 9 Allowance - end of period $ 1,054 $ 726

Note 7 - Fair Value of Financia

Note 7 - Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	(7) Fair Value of Financial Instruments Financial instruments recorded at fair value in the consolidated balance sheets, or disclosed at fair value in the footnotes, are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels defined by ASC 820, Fair Value Measurements and Disclosures Level 1 Valued based on unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 Valued based on either directly or indirectly observable prices for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 Valued based on management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. The following table presents the fair value and hierarchy levels, for financial assets that are measured at fair value on a recurring basis (in thousands): September 30, December 31, 2023 Level 3 Purchase price contingent consideration: Accrued contingent consideration (earn-out) $ 10,001 $ 13,096 Present value of non-competition payments 6,895 8,474 In connection with the acquisitions of Welch and Marble in 2024, and DAS Medical in 2021, the Company is required to make contingent payments, subject to the entities achieving certain financial performance thresholds. The contingent consideration payments for the Welch, Marble and the DAS Medical acquisitions are up to $6 million, $500 thousand and $20 million, respectively. The fair value of the liability for the contingent consideration payments recognized upon the acquisition as part of the purchase accounting opening balance sheets totaled approximately $800 thousand, $400 thousand and $5.2 million for the Welch, Marble and the DAS Medical acquisitions, respectively, and was estimated by discounting to present value the probability-weighted contingent payments expected to be made. Assumptions used in the initial calculation were management’s financial forecasts, discount rate and various volatility factors. The ultimate settlement of contingent consideration could deviate from current estimates based on the actual results of these financial measures. Contingent consideration is considered to be a Level 3 financial liability that is re-measured each reporting period. The fair value of the liability for the contingent consideration payments recognized at September 30, 2024 totaled approximately $10.0 million out of the remaining potential payments of $16.5 million. The change in fair value of contingent consideration for the acquisitions is included in change in fair value of contingent consideration in the condensed consolidated statements of comprehensive income. Also in connection with the DAS Medical and Advant Medical acquisitions, the Company entered into Non-Competition Agreements with the beneficiaries (certain previous owners of DAS and Advant) and the Company has agreed to pay additional consideration to the parties to the Non-Competition Agreements, including an aggregate of $10.0 million in payments over the ten The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, that are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company’s long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the Company.

Note 8 - Share-based Compensati

Note 8 - Share-based Compensation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	(8) Share-Based Compensation Share-based compensation is measured on the grant date based on the fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). The Company issues share-based awards through two plans that are described in detail in the notes to the consolidated financial statements for the year ended December 31, 2023. The compensation cost charged against income from those plans is included in selling, general & administrative expenses as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, Share-based compensation related to: 2024 2023 2024 2023 Common stock grants $ 100 $ 100 $ 300 $ 300 Stock option grants 127 112 357 320 Restricted Stock Unit Awards ("RSUs") 1,312 985 4,130 2,830 Total share-based compensation $ 1,539 $ 1,197 $ 4,787 $ 3,450 The total income tax benefit recognized in the condensed consolidated statements of comprehensive income for share-based compensa‐tion arrangements was approximately $394 thousand and $1.9 million for the three-and-nine-month periods ended September 30, 2024, respectively, and approximately $310 thousand and $1.9 million for the three-and-nine-month periods ended September 30, 2023. Common Stock Grants The compensation expense for common stock granted during the nine-month period ended September 30, 2024, was determined based on the market price of the shares on the date of grant. Stock Option Grants The following is a summary of stock option activity under all plans for the nine-month period ended September 30, 2024: Shares Under Options Weighted Average Exercise Price (per share) Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2023 78,488 $ 39.98 Granted 2,958 260.92 Exercised (6,568 ) 32.35 Outstanding at September 30, 2024 74,878 $ 67.67 5.17 $ 18,669 Exercisable at September 30, 2024 67,952 $ 56.36 5.08 $ 17,690 Vested and expected to vest at September 30, 2024 74,878 $ 67.67 5.17 $ 18,669 On June 6, 2024, the Company granted options to its directors for the purchase of 2,958 shares of the Company’s common stock at that day’s closing price of $260.92. The compensation expense related to these grants was determined as the fair value of the options using the Black-Scholes option pricing model based on the following assumptions: Expected volatility 39.7 % Expected dividends None Risk-free interest rate 4.3 % Exercise price $ 260.92 Expected term 6.3 Weighted-average grant date fair value $ 121.61 The stock volatility for each grant is determined based on a review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected option term, and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods correspond‐ing with the expected term of the option. The expected term is estimated based on historical option exercise activity. During the nine-month periods ended September 30, 2024 and 2023, the total intrinsic value of all options exercised (i.e., the difference between the market price and the price paid to exercise the options) was approximately $652 thousand and $3.0 million, respectively, and the total amount of consideration received by the Company from the exercised options was approximately $212 thousand and $789 thousand, respectively. At its discretion, the Company allows option holders to surrender previously owned common stock in lieu of paying the exercise price and withholding taxes. During the nine-month period ended September 30, 2024, 653 shares were surrendered at an average market price of $162.93. During the nine-month period ended September 30, 2023, 861 shares were surrendered at an average market price of $127.05. Restricted Stock Unit awards The following table summarizes information about RSU activity during the nine-month period ended September 30, 2024: Restricted Stock Units Weighted Average Outstanding at December 31, 2023 95,693 $ 64.82 Awarded 31,663 175.30 Shares vested (50,582 ) 79.53 Shares forfeited (559 ) 135.81 Outstanding at September 30, 2024 76,215 $ 95.82 At the Company’s discretion, upon vesting, RSU holders are given the option to net-share settle to cover the required minimum withholding tax and the remaining amount is converted into the equivalent number of common shares and issued to the RSU holder. During the nine-month periods ended September 30, 2024 and 2023, 21,914 shares and 20,457 shares were surrendered at an average market price of $216.80 and $117.95, respectively. As of September 30, 2024, the Company had approximately $6.7 million of unrecognized compensation expense that is expected to be recognized over a period of 2.5 years.

Note 9 - Inventories

Note 9 - Inventories	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	(9) Inventories Inventories are stated at the lower of cost (determined using the first-in, first-out method) or net realizable value, and consist of the following at the stated dates (in thousands): September 30, December 31, 2024 2023 Raw materials $ 63,530 $ 53,539 Work in process 8,846 7,821 Finished goods 16,314 8,831 Total inventory $ 88,690 $ 70,191

Note 10 - Property, Plant and E

Note 10 - Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	(10) Property, Plant and Equipment Property, plant, and equipment consist of the following (in thousands): September 30, December 31, 2024 2023 Land and improvements $ 5,850 $ 4,849 Buildings and improvements 38,079 34,735 Leasehold improvements 9,418 8,226 Machinery & equipment 65,259 58,343 Furniture, fixtures, computers & software 7,375 6,324 Construction in progress 7,333 6,845 Property, plant and equipment $ 133,314 $ 119,322 Accumulated depreciation and amortization (63,003 ) (57,185 ) Net property, plant and equipment $ 70,311 $ 62,137

Note 10 - Leases

Note 10 - Leases	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Lessee, Operating and Finance Leases [Text Block]	(11) Leases The Company has operating and finance leases for offices, manufacturing plants, vehicles and certain office and manufacturing equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for each separate lease component of a contract and its associated non-lease components as a single lease component, thus causing all fixed payments to be capitalized. Variable lease payment amounts that cannot be determined at the commencement of the lease such as increases in lease payments based on changes in index rates or usage, are not included in the right of use (“ROU”) assets or lease liabilities. These are expensed as incurred and recorded as variable lease expense. The Company determines if an arrangement is a lease at the inception of a contract. Operating and finance lease ROU assets and operating and finance lease liabilities are stated separately in the condensed consolidated balance sheet. ROU assets represent the Company's right to use an underlying asset during the lease term and lease liabilities represent the Company's obligation to make lease payments pursuant to the lease. ROU assets and lease liabilities are recognized at commencement date based on the net present value of fixed lease payments over the lease term. The lease term assumed in the determination of the ROU assets and lease liabilities includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. ROU assets are also adjusted for any deferred or accrued rent. As the Company's leases do not typically provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. ROU assets and lease liabilities consist of the following (in thousands): September 30, December 31, 2024 2023 Operating lease ROU assets $ 15,340 $ 13,437 Finance lease ROU assets 107 151 Total ROU assets $ 15,447 $ 13,588 Operating lease liabilities - current $ 3,919 $ 3,162 Finance lease liabilities - current 60 60 Total lease liabilities - current $ 3,979 $ 3,222 Operating lease liabilities - long-term $ 11,911 $ 10,719 Finance lease liabilities - long-term 50 96 Total lease liabilities - long-term $ 11,961 $ 10,815 The components of lease costs for the nine-month periods ended September 30, 2024 and 2023 consist of the following (in thousands): Nine Months Ended September 30, 2024 2023 Lease Cost: Finance lease cost: Amortization of right of use assets $ 71 $ 45 Interest on lease liabilities 5 3 Operating lease cost 2,776 2,304 Variable lease cost 241 240 Short-term lease cost 136 38 Total lease cost $ 3,229 $ 2,630 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 2,723 $ 2,197 Financing cash flows from finance leases 58 47 Weighted-average remaining lease term (years): Finance 1.40 2.79 Operating 4.21 4.57 Weighted-average discount rate: Finance 2.11 % 2.10 % Operating 4.87 % 3.42 % The aggregate future lease payments for leases as of September 30, 2024 are as follows (in thousands): Operating Finance Remainder of 2024 $ 1,046 $ 63 2025 3,844 40 2026 3,377 10 2027 2,961 - 2028 1,855 - Thereafter 5,329 - Total lease payments 18,412 113 Less: Interest (2,582 ) (3 ) Present value of lease liabilities $ 15,830 $ 110

Note 12 - Income Per Share

Note 12 - Income Per Share	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	(12) Income Per Share Basic income per share is based on the weighted average number of shares of common stock outstanding. Diluted income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalent shares outstanding during each period. The weighted average number of shares used to compute basic and diluted net income per share consisted of the following (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Basic weighted average common shares outstanding 7,674 7,639 7,666 7,619 Weighted average common equivalent shares due to restricted stock, stock options and RSUs 98 70 97 78 Diluted weighted average common shares outstanding 7,772 7,709 7,763 7,697 The computation of diluted earnings per share excludes the effect of the potential exercise of stock awards, including stock options, when the average market price of the common stock is lower than the exercise price of the related stock options during the period. These outstanding stock options are not included in the computa‐tion of diluted income per share because the effect would be antidilutive. For the three- and nine-month periods ended September 30, 2024, the number of stock awards excluded from the computation were zero 2,958

Note 13 - Segment Data

Note 13 - Segment Data	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	(13) Segment Data The Company consists of a single Information about Geographic Areas Revenues shipped to customers outside of the United States comprised approximately 14.7% and 17.1% of the Company’s consolidated revenues for the three- and nine-month periods ended September 30, 2024, respectively. Revenues shipped to customers outside of the United States comprised approximately 15.4% and 16.8% of the Company’s consolidated revenues for the three- and nine-month periods ended September 30, 2023, respectively. Approximately 18.4% of all long-lived assets are located outside of the United States. Information about Major Customers Sales to two Sales to two Sales to one On September 30, 2024, three On December 31, 2023, two The Company’s products are primarily sold to customers within the Medical, Industrial/Other markets, Aerospace & Defense, and Automotive markets. Sales by market for the three and nine months ended September 30, 2024 and 2023 are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Market Net Sales % Net Sales % Net Sales % Net Sales % Medical $ 132,623 91.4 % $ 87,127 86.5 % $ 318,079 88.3 % $ 257,092 86.1 % Industrial/ Other 4,637 3.2 % 4,902 4.9 % 14,484 3.9 % 15,834 5.3 % Aerospace & Defense 4,444 3.1 % 4,377 4.3 % 16,401 4.6 % 12,828 4.3 % Automotive 3,461 2.3 % 4,378 4.3 % 11,387 3.2 % 12,821 4.3 % Net Sales $ 145,165 100.0 % $ 100,784 100.0 % $ 360,351 100.0 % $ 298,575 100.0 %

Note 14 - Goodwill and Other In

Note 14 - Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	(14) Goodwill and Other Intangible Assets The changes in the carrying amount of goodwill for the nine months ended September 30, 2024 are as follows (in thousands): Goodwill December 31, 2023 $ 113,263 Acquired in Marble Medical business combination 2,564 Acquired in AJR Enterprises business combination 41,710 Acquired in Welch Fluorocarbon business combination 19,367 Acquired in AQF business combination 27,651 Foreign currency translation 177 September 30, 2024 $ 204,732 The carrying values of the Company’s definite lived intangible assets as of September 30, 2024 are as follows (in thousands): Intelletual Property / Tradename & Brand Non- Customer Total Weighted-average amortization period 12.0 years 8.8 years 20.0 years Gross amount $ 25,931 $ 6,791 $ 120,008 $ 152,730 Accumulated amortization (2,085 ) (1,971 ) (13,956 ) (18,012 ) Net balance $ 23,846 $ 4,820 $ 106,052 $ 134,718 Amortization expense related to intangible assets was approximately $2.0 million and $4.2 million for the three- and nine-month periods ended September 30, 2024, respectively, and $1.0 million and $3.1 million for the three- and nine-month periods ended September 30, 2023, respectively. The estimated remaining amortization expense as of September 30, 2024 is as follows (in thousands): Remainder of 2024 $ 2,177 2025 8,710 2026 8,707 2027 8,654 2028 8,551 2029 8,604 Thereafter 89,315 Total $ 134,718

Note 15 - Other Long-term Liabi

Note 15 - Other Long-term Liabilities	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	(15) Other Long-Term Liabilities Other long-term liabilities consist of the following (in thousands): September 30, December 31, 2024 2023 Accrued contingent consideration (earn-out) $ 4,751 $ 8,096 Present value of non-competition payments 5,387 6,586 Other 806 499 $ 10,944 $ 15,181

Note 16 - Income Taxes

Note 16 - Income Taxes	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	(16) Income Taxes The determination of income tax expense in the accompanying unaudited condensed consolidated statements of income is based upon the estimated effective tax rate for the year, adjusted for the impact of any discrete items which are accounted for in the period in which they occur. The Company recorded income tax expense of approximately 22.9% and 21.0% of income before income tax expense for the three- and nine-month periods ended September 30, 2024, respectively, and 17.3% and 20.7% of income before income tax expense for the three- and nine-month periods ended September 30, 2023, respectively

Note 17 - Debt

Note 17 - Debt	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	(17) Debt On June 27, 2024, the Company, as the borrower, entered into a secured $275 million Amended and Restated Credit Agreement (the “Third Amended and Restated Credit Agreement”) with certain of the Company’s subsidiaries (the “Subsidiary Guarantors”) and Bank of America, N.A., in its capacity as the initial lender, Administrative Agent, Swingline Lender and L/C Issuer, and certain other lenders from time-to-time party thereto. The Third Amended and Restated Credit Agreement amends and restates the Company’s prior credit agreement, originally dated as of December 22, 2021. The credit facilities under the Third Amended and Restated Credit Agreement consist of a secured term loan to the Company of $125 million and a secured revolving credit facility, under which the Company may borrow up to $150 million. The Third Amended and Restated Credit Facilities mature on June 27, 2029. This maturity date is subject to acceleration and the Company could be subject to additional fees and expenses in certain circumstances should one or more events of default described in the Third Amended and Restated Credit Agreement occur. The secured term loan requires quarterly principal payments of $3,125,000 that commence on December 31, 2024. The proceeds of the Third Amended and Restated Credit Agreement may be used for general corporate purposes, including funding the acquisition of AJR Enterprises, LLC (see Note 2 for more information regarding this acquisition), as well as certain other permitted acquisitions. The Company’s obligations under the Third Amended and Restated Credit Agreement are guaranteed by Subsidiary Guarantors and secured by substantially all assets of the Company. The Third Amended and Restated Credit Facilities call for interest at SOFR plus a margin that ranges from 1.25% to 2.25% or, at the discretion of the Company, the bank’s prime rate plus a margin that ranges from .25 At September 30, 2024, the Company had approximately $212.0 million in outstanding borrowings under the Third Amended and Restated Credit Agreement, and also had approximately $0.7 million in standby letters of credit outstanding, drawable as a financial guarantee on worker’s compensation insurance policies. At September 30, 2024, the applicable interest rate was approximately 6.5% and the Company was in compliance with all covenants under the Third Amended and Restated Credit Agreement. Long-term debt consists of the following (in thousands): September 30, 2024 Revolving credit facility $ 87,000 Term loan 125,000 Total long-term debt 212,000 Current portion (12,500 ) Long-term debt, excluding current portion $ 199,500 Future maturities of long-term debt at September 30, 2024 are as follows ( in thousands Term Loan Revolving Total Remainder of 2024 $ 3,125 $ - $ 3,125 2025 12,500 - 12,500 2026 12,500 - 12,500 2027 12,500 - 12,500 2028 12,500 - 12,500 2029 71,875 87,000 158,875 $ 125,000 $ 87,000 $ 212,000

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	OTHER INFORMATION During the third quarter of fiscal 2024, none
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 2 - Acquisition (Tables)

Note 2 - Acquisition (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Purchase Price Allocation Cash $ 815 Accounts receivable 872 Inventory 494 Other current assets 24 Property, plant, and equipment 1,018 Customer contracts & relationships 250 Intellectual property 300 Non-compete agreement 50 Goodwill 2,564 Total assets acquired 6,387 Accounts payable (41 ) Accrued expenses (519 ) Total liabilities assumed (560 ) Total assets acquired, net of liabilities assumed 5,827 Less: cash acquired (815 ) Purchase price, net of cash acquired $ 5,012 Purchase Price Allocation Cash $ 3,000 Accounts receivable 17,138 Inventory 9,229 Other current assets 210 Property, plant, and equipment 1,149 Customer contracts & relationships 40,389 Intellectual property 8,245 Non-compete agreement 661 Lease right of use assets 2,024 Goodwill 41,710 Total assets acquired 123,755 Accounts payable (1,103 ) Accrued expenses (7,092 ) Lease liabilities (2,024 ) Total liabilities assumed (10,219 ) Total assets acquired, net of liabilities assumed 113,536 Less: cash acquired (3,000 ) Purchase price, net of cash acquired $ 110,536 Purchase Price Allocation Cash $ 3,817 Accounts receivable 1,506 Inventory 1,969 Other current assets 115 Property, plant, and equipment 824 Customer contracts & relationships 3,697 Intellectual property 7,859 Non-compete agreement 176 Lease right of use assets 150 Goodwill 19,367 Total assets acquired 39,480 Accounts payable (215 ) Accrued expenses (77 ) Lease liabilities (150 ) Total liabilities assumed (442 ) Total assets acquired, net of liabilities assumed 39,038 Less: cash acquired (3,817 ) Net assets acquired, net of cash acquired $ 35,221 Purchase Price Allocation Cash $ 3,381 Accounts receivable 2,237 Inventory 1,150 Other current assets 204 Property, plant, and equipment 976 Customer contracts & relationships 10,363 Intellectual property 2,343 Non-compete agreement 395 Lease right of use assets 1,723 Equity Method Investment 5,623 Goodwill 27,651 Total assets acquired 56,046 Accounts payable (1,890 ) Accrued expenses (487 ) Deferred taxes (1,711 ) Lease liabilities (1,723 ) Total liabilities assumed (5,811 ) Total assets acquired, net of liabilities assumed 50,235 Less: cash acquired (3,381 ) Purchase price, net of cash acquired $ 46,854
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Sales $ 148,515 $ 128,136 $ 435,494 $ 378,105 Operating Income $ 25,039 $ 17,648 $ 70,567 $ 55,430 Net Income $ 16,433 $ 11,697 $ 47,495 $ 35,492 Earnings per share: Basic $ 2.14 $ 1.53 $ 6.20 $ 4.66 Diluted $ 2.11 $ 1.52 $ 6.12 $ 4.61

Note 4 - Revenue Recognition (T

Note 4 - Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, Net sales of: 2024 2023 2024 2023 Products $ 142,877 $ 98,261 $ 351,395 $ 291,612 Tooling and Machinery 1,420 1,431 5,977 2,985 Engineering services 868 1,092 2,979 3,978 Total net sales $ 145,165 $ 100,784 $ 360,351 $ 298,575
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Contract Liabilities Nine Months Ended 2024 2023 Deferred revenue - beginning of period $ 6,616 $ 4,679 Deferred revenue acquired in Welch Fluorocarbon acquisition 8 - Increases due to consideration received from customers 3,302 3,169 Revenue recognized (4,128 ) (4,034 ) Deferred revenue - end of period $ 5,798 $ 3,814 Contract Assets Nine Months Ended 2024 2023 Unbilled Receivables - beginning of period $ 114 $ 270 Increases due to revenue recognized, not invoiced to customers 1,620 2,898 Decreases due to customer invoicing (1,532 ) (3,020 ) Unbilled Receivables - end of period $ 202 $ 148

Note 5 - Supplemental Cash Fl_2

Note 5 - Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Nine Months Ended September 30, 2024 2023 Cash paid for: Interest $ 4,427 $ 2,838 Income taxes, net of refunds $ 9,505 $ 10,174 Non-cash investing and financing activities: Capital additions accrued but not yet paid $ 158 $ 185 Operating lease right of use assets $ 4,043 $ 2,492 Operating lease liabilities $ (4,056 ) $ (2,548 ) Financing lease right of use assets $ 35 $ - Financing lease liablities $ (58 ) $ -

Note 6 - Receivables and Allo_2

Note 6 - Receivables and Allowance for Credit Losses (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	September 30, December 31, December 31, 2024 2023 2022 Accounts receivable–trade $ 90,205 $ 65,176 $ 55,850 Less allowance for credit losses (1,054 ) (727 ) (733 ) Receivables, net $ 89,151 $ 64,449 $ 55,117
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	Allowance for Credit Nine Months Ended 2024 2023 Allowance - beginning of period $ 727 $ 733 Adjustment for expected credit losses 355 (5 ) Amounts written off against the allowance (28 ) (11 ) Recoveries - 9 Allowance - end of period $ 1,054 $ 726

Note 7 - Fair Value of Financ_2

Note 7 - Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	September 30, December 31, 2023 Level 3 Purchase price contingent consideration: Accrued contingent consideration (earn-out) $ 10,001 $ 13,096 Present value of non-competition payments 6,895 8,474

Note 8 - Share-based Compensa_2

Note 8 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Employee Service Share Based Compensation Allocation of Recognized Period Costs, By Award Type [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, Share-based compensation related to: 2024 2023 2024 2023 Common stock grants $ 100 $ 100 $ 300 $ 300 Stock option grants 127 112 357 320 Restricted Stock Unit Awards ("RSUs") 1,312 985 4,130 2,830 Total share-based compensation $ 1,539 $ 1,197 $ 4,787 $ 3,450
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Under Options Weighted Average Exercise Price (per share) Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2023 78,488 $ 39.98 Granted 2,958 260.92 Exercised (6,568 ) 32.35 Outstanding at September 30, 2024 74,878 $ 67.67 5.17 $ 18,669 Exercisable at September 30, 2024 67,952 $ 56.36 5.08 $ 17,690 Vested and expected to vest at September 30, 2024 74,878 $ 67.67 5.17 $ 18,669
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected volatility 39.7 % Expected dividends None Risk-free interest rate 4.3 % Exercise price $ 260.92 Expected term 6.3 Weighted-average grant date fair value $ 121.61
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Restricted Stock Units Weighted Average Outstanding at December 31, 2023 95,693 $ 64.82 Awarded 31,663 175.30 Shares vested (50,582 ) 79.53 Shares forfeited (559 ) 135.81 Outstanding at September 30, 2024 76,215 $ 95.82

Note 9 - Inventories (Tables)

Note 9 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 2024 2023 Raw materials $ 63,530 $ 53,539 Work in process 8,846 7,821 Finished goods 16,314 8,831 Total inventory $ 88,690 $ 70,191

Note 10 - Property, Plant and_2

Note 10 - Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, 2024 2023 Land and improvements $ 5,850 $ 4,849 Buildings and improvements 38,079 34,735 Leasehold improvements 9,418 8,226 Machinery & equipment 65,259 58,343 Furniture, fixtures, computers & software 7,375 6,324 Construction in progress 7,333 6,845 Property, plant and equipment $ 133,314 $ 119,322 Accumulated depreciation and amortization (63,003 ) (57,185 ) Net property, plant and equipment $ 70,311 $ 62,137

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Leases, Right-of-Use Assets and Liabilities [Table Text block]	September 30, December 31, 2024 2023 Operating lease ROU assets $ 15,340 $ 13,437 Finance lease ROU assets 107 151 Total ROU assets $ 15,447 $ 13,588 Operating lease liabilities - current $ 3,919 $ 3,162 Finance lease liabilities - current 60 60 Total lease liabilities - current $ 3,979 $ 3,222 Operating lease liabilities - long-term $ 11,911 $ 10,719 Finance lease liabilities - long-term 50 96 Total lease liabilities - long-term $ 11,961 $ 10,815
Lease, Cost [Table Text Block]	Nine Months Ended September 30, 2024 2023 Lease Cost: Finance lease cost: Amortization of right of use assets $ 71 $ 45 Interest on lease liabilities 5 3 Operating lease cost 2,776 2,304 Variable lease cost 241 240 Short-term lease cost 136 38 Total lease cost $ 3,229 $ 2,630 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 2,723 $ 2,197 Financing cash flows from finance leases 58 47 Weighted-average remaining lease term (years): Finance 1.40 2.79 Operating 4.21 4.57 Weighted-average discount rate: Finance 2.11 % 2.10 % Operating 4.87 % 3.42 %
Lessee, Operating and Finance Leases, Liability, Maturity [Table Text Block]	Operating Finance Remainder of 2024 $ 1,046 $ 63 2025 3,844 40 2026 3,377 10 2027 2,961 - 2028 1,855 - Thereafter 5,329 - Total lease payments 18,412 113 Less: Interest (2,582 ) (3 ) Present value of lease liabilities $ 15,830 $ 110

Note 12 - Income Per Share (Tab

Note 12 - Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Basic weighted average common shares outstanding 7,674 7,639 7,666 7,619 Weighted average common equivalent shares due to restricted stock, stock options and RSUs 98 70 97 78 Diluted weighted average common shares outstanding 7,772 7,709 7,763 7,697

Note 13 - Segment Data (Tables)

Note 13 - Segment Data (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Market Net Sales % Net Sales % Net Sales % Net Sales % Medical $ 132,623 91.4 % $ 87,127 86.5 % $ 318,079 88.3 % $ 257,092 86.1 % Industrial/ Other 4,637 3.2 % 4,902 4.9 % 14,484 3.9 % 15,834 5.3 % Aerospace & Defense 4,444 3.1 % 4,377 4.3 % 16,401 4.6 % 12,828 4.3 % Automotive 3,461 2.3 % 4,378 4.3 % 11,387 3.2 % 12,821 4.3 % Net Sales $ 145,165 100.0 % $ 100,784 100.0 % $ 360,351 100.0 % $ 298,575 100.0 %

Note 14 - Goodwill and Other _2

Note 14 - Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Goodwill [Table Text Block]	Goodwill December 31, 2023 $ 113,263 Acquired in Marble Medical business combination 2,564 Acquired in AJR Enterprises business combination 41,710 Acquired in Welch Fluorocarbon business combination 19,367 Acquired in AQF business combination 27,651 Foreign currency translation 177 September 30, 2024 $ 204,732
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Intelletual Property / Tradename & Brand Non- Customer Total Weighted-average amortization period 12.0 years 8.8 years 20.0 years Gross amount $ 25,931 $ 6,791 $ 120,008 $ 152,730 Accumulated amortization (2,085 ) (1,971 ) (13,956 ) (18,012 ) Net balance $ 23,846 $ 4,820 $ 106,052 $ 134,718
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Remainder of 2024 $ 2,177 2025 8,710 2026 8,707 2027 8,654 2028 8,551 2029 8,604 Thereafter 89,315 Total $ 134,718

Note 15 - Other Long-term Lia_2

Note 15 - Other Long-term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Other Noncurrent Liabilities [Table Text Block]	September 30, December 31, 2024 2023 Accrued contingent consideration (earn-out) $ 4,751 $ 8,096 Present value of non-competition payments 5,387 6,586 Other 806 499 $ 10,944 $ 15,181

Note 17 - Debt (Tables)

Note 17 - Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Debt [Table Text Block]	September 30, 2024 Revolving credit facility $ 87,000 Term loan 125,000 Total long-term debt 212,000 Current portion (12,500 ) Long-term debt, excluding current portion $ 199,500
Schedule of Maturities of Long-Term Debt [Table Text Block]	Term Loan Revolving Total Remainder of 2024 $ 3,125 $ - $ 3,125 2025 12,500 - 12,500 2026 12,500 - 12,500 2027 12,500 - 12,500 2028 12,500 - 12,500 2029 71,875 87,000 158,875 $ 125,000 $ 87,000 $ 212,000

Note 2 - Acquisition (Details T

Note 2 - Acquisition (Details Textual) $ in Thousands, € in Millions						3 Months Ended		9 Months Ended
	Aug. 23, 2024 USD ($)	Aug. 23, 2024 EUR (€)	Jul. 15, 2024 USD ($)	Jul. 01, 2024 USD ($)	Jun. 24, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Payments to Acquire Businesses, Net of Cash Acquired								$ 196,432	$ 0
Acquisition costs						$ 732	$ 0	$ 1,676	$ 0
Marble Medical, Inc [Member]
Business Acquisition, Percentage of Voting Interests Acquired					100%	100%		100%
Business Combination, Consideration Transferred					$ 4,500
Business Combination, Contingent Consideration, Liability					400	$ 400		$ 400
Business Combination, Working Capital Adjustment					100
Payments to Acquire Businesses, Net of Cash Acquired					5,012
Acquisition costs								146
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual								2,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual								$ 300
Marble Medical, Inc [Member] | Maximum [Member] | Achievement of Sales Targets [Member]
Business Combination, Consideration Transferred, Liabilities Incurred					$ 500
AJR Enterprises, LLC [Member]
Business Acquisition, Percentage of Voting Interests Acquired				100%		100%		100%
Business Combination, Consideration Transferred				$ 110,000
Payments to Acquire Businesses, Net of Cash Acquired				110,536
Acquisition costs								$ 589
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual								27,700
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual								$ 5,700
Disposal Group, Including Discontinued Operation, Consideration				$ 500
Welch Fluorocarbon, Inc [Member]
Business Acquisition, Percentage of Voting Interests Acquired			100%			100%		100%
Business Combination, Consideration Transferred			$ 34,600
Business Combination, Contingent Consideration, Liability			800			$ 800		$ 800
Payments to Acquire Businesses, Net of Cash Acquired			35,221
Acquisition costs								271
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual								3,200
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual								200
Disposal Group, Including Discontinued Operation, Consideration			200
Payments to Acquire Real Estate			3,200
Welch Fluorocarbon, Inc [Member] | Maximum [Member] | Achievement of EBITDA Targets [Member]
Business Combination, Consideration Transferred, Liabilities Incurred			$ 6,000
AQF [Member]
Business Acquisition, Percentage of Voting Interests Acquired	100%	100%
Business Combination, Working Capital Adjustment	$ 900
Payments to Acquire Businesses, Net of Cash Acquired	46,854	€ 43
Acquisition costs								639
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual								2,100
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual								$ 500
Payments to Acquire Businesses, Gross	$ 47,800

Note 2 - Acquisitions - Assets

Note 2 - Acquisitions - Assets Acquires and Liabilities Assumed (Details) $ in Thousands, € in Millions						9 Months Ended
	Aug. 23, 2024 USD ($)	Aug. 23, 2024 EUR (€)	Jul. 15, 2024 USD ($)	Jul. 01, 2024 USD ($)	Jun. 24, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Goodwill						$ 204,732		$ 113,263
Payments to Acquire Businesses, Net of Cash Acquired						$ 196,432	$ 0
Marble Medical, Inc [Member]
Cash					$ 815
Accounts receivable					872
Inventory					494
Other current assets					24
Property, plant, and equipment					1,018
Goodwill					2,564
Total assets acquired					6,387
Accounts payable					41
Accrued expenses					(519)
Total liabilities assumed					560
Total assets acquired, net of liabilities assumed					5,827
Less: cash acquired					815
Payments to Acquire Businesses, Net of Cash Acquired					5,012
Marble Medical, Inc [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships					250
Marble Medical, Inc [Member] | Intellectual Property [Member]
Customer contracts & relationships					300
Marble Medical, Inc [Member] | Noncompete Agreements [Member]
Customer contracts & relationships					$ 50
AJR Enterprises, LLC [Member]
Cash				$ 3,000
Accounts receivable				17,138
Inventory				9,229
Other current assets				210
Property, plant, and equipment				1,149
Goodwill				41,710
Lease right of use assets				2,024
Total assets acquired				123,755
Accounts payable				1,103
Accrued expenses				(7,092)
Total liabilities assumed				10,219
Total assets acquired, net of liabilities assumed				113,536
Lease liabilities				2,024
Less: cash acquired				3,000
Payments to Acquire Businesses, Net of Cash Acquired				110,536
AJR Enterprises, LLC [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships				40,389
AJR Enterprises, LLC [Member] | Intellectual Property [Member]
Customer contracts & relationships				8,245
AJR Enterprises, LLC [Member] | Noncompete Agreements [Member]
Customer contracts & relationships				$ 661
Welch Fluorocarbon, Inc [Member]
Cash			$ 3,817
Accounts receivable			1,506
Inventory			1,969
Other current assets			115
Property, plant, and equipment			824
Goodwill			19,367
Lease right of use assets			150
Total assets acquired			39,480
Accounts payable			215
Accrued expenses			(77)
Total liabilities assumed			442
Total assets acquired, net of liabilities assumed			39,038
Lease liabilities			150
Less: cash acquired			3,817
Payments to Acquire Businesses, Net of Cash Acquired			35,221
Welch Fluorocarbon, Inc [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships			3,697
Welch Fluorocarbon, Inc [Member] | Intellectual Property [Member]
Customer contracts & relationships			7,859
Welch Fluorocarbon, Inc [Member] | Noncompete Agreements [Member]
Customer contracts & relationships			$ 176
AQF [Member]
Cash	$ 3,381
Accounts receivable	2,237
Inventory	1,150
Other current assets	204
Property, plant, and equipment	976
Goodwill	27,651
Lease right of use assets	1,723
Total assets acquired	56,046
Equity Method Investment	5,623
Accounts payable	1,890
Accrued expenses	(487)
Lease liabilities	1,723
Less: cash acquired	3,381
Deferred taxes	1,711
Payments to Acquire Businesses, Net of Cash Acquired	46,854	€ 43
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	5,811
Total assets acquired, net of liabilities assumed	50,235
AQF [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships	10,363
AQF [Member] | Intellectual Property [Member]
Customer contracts & relationships	2,343
AQF [Member] | Noncompete Agreements [Member]
Customer contracts & relationships	$ 395

NoteTable (Details)

NoteTable (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Sales	$ 148,515	$ 128,136	$ 435,494	$ 378,105
Operating Income	25,039	17,648	70,567	55,430
Net Income	$ 16,433	$ 11,697	$ 47,495	$ 35,492
Basic (in dollars per share)	$ 2.14	$ 1.53	$ 6.2	$ 4.66
Diluted (in dollars per share)	$ 2.11	$ 1.52	$ 6.12	$ 4.61

Note 3 - Equity Method Invest_2

Note 3 - Equity Method Investment (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Equity Method Investments	$ 5,623	$ 0
AQF Asia [Member]
Equity Method Investment, Ownership Percentage	50%

Note 4 - Revenue Recognition (D

Note 4 - Revenue Recognition (Details Textual) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Deferred Revenue [Member]
Contract with Customer, Liability, Revenue Recognized	$ 3.4	$ 2.4

Note 4 - Revenue Recognition -

Note 4 - Revenue Recognition - Revenue Disaggregated by the Major Types of Goods and Services Sold (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net sales	$ 145,165	$ 100,784	$ 360,351	$ 298,575
Product [Member]
Net sales	142,877	98,261	351,395	291,612
Tooling and Machinery [Member]
Net sales	1,420	1,431	5,977	2,985
Engineering and Development [Member]
Net sales	$ 868	$ 1,092	$ 2,979	$ 3,978

Note 4 - Revenue Recognition _2

Note 4 - Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Deferred revenue - beginning of period	$ 6,616	$ 4,679
Unbilled receivables - beginning of period	114	270
Deferred revenue acquired in Welch Fluorocarbon acquisition	8	0
Increases due to revenue recognized, not invoiced to customers	1,620	2,898
Increases due to consideration received from customers	3,302	3,169
Decreases due to customer invoicing	(1,532)	(3,020)
Revenue recognized	(4,128)	(4,034)
Unbilled receivables - end of period	202	148
Deferred revenue - end of period	$ 5,798	$ 3,814

Note 5 - Supplemental Cash Fl_3

Note 5 - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Interest	$ 4,427	$ 2,838
Income taxes, net of refunds	9,505	10,174
Capital additions accrued but not yet paid	158	185
Operating lease right of use assets	4,043	2,492
Operating lease liabilities	(4,056)	(2,548)
Financing lease right of use assets	35	0
Financing lease liablities	$ (58)	$ 0

Note 6 - Receivables and Allo_3

Note 6 - Receivables and Allowance for Credit Losses - Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounts receivable–trade	$ 90,205	$ 65,176	$ 55,850
Less allowance for credit losses	(1,054)	(727)	(733)
Receivables, net	$ 89,151	$ 64,449	$ 55,117

Note 6 - Receivables and Allo_4

Note 6 - Receivables and Allowance for Credit Losses - Summary of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Allowance - beginning of period	$ 727	$ 733
Adjustment for expected credit losses	355	(5)
Amounts written off against the allowance	(28)	(11)
Recoveries	0	9
Allowance - end of period	$ 1,054	$ 726

Note 7 - Fair Value of Financ_3

Note 7 - Fair Value of Financial Instruments (Details Textual) € in Thousands, $ in Millions		3 Months Ended	9 Months Ended
	Dec. 22, 2021 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 EUR (€)	Jul. 15, 2024 USD ($)	Jun. 24, 2024 USD ($)
Present Value of Non-competition Agreement			$ 6.9
Welch Fluorocarbon, Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			6
Business Combination, Contingent Consideration, Liability			0.8		$ 0.8
Marble Medical, Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			0.5
Business Combination, Contingent Consideration, Liability			0.4			$ 0.4
DAS Medical [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			20
Business Combination, Contingent Consideration, Liability			5.2
DAS Medical [Member] | Non-Competition Agreements [Member]
Payments to Acquire Businesses, Gross	$ 10	$ 1.7
Business Combination, Agreement Term (Year)	10 years
Marble Medical and DAS Medical [Member]
Business Combination, Contingent Consideration, Liability			10
Business Combination, Consideration Transferred, Liabilities Incurred			$ 16.5
Advant Medical [Member] | Non-Competition Agreements [Member]
Payments to Acquire Businesses, Gross | €				€ 375
Business Combination, Agreement Term (Year)			5 years	5 years

Note 7 - Fair Value of Financ_4

Note 7 - Fair Value of Financial Instruments - Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Present value of non-competition payments	$ 6,900
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Accrued contingent consideration (earn-out)	10,001	$ 13,096
Present value of non-competition payments	$ 6,895	$ 8,474

Note 8 - Share-based Compensa_3

Note 8 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expense, Tax Benefit	$ 394	$ 310	$ 1,900	$ 1,900
Share Price (in dollars per share)	$ 260.92		$ 260.92
Proceeds from Stock Options Exercised			$ 107	680
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 6,700		$ 6,700
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years 6 months
Employee and Nonemployee Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			2,958
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 652,000	3,000
Proceeds from Stock Options Exercised			$ 212	$ 789
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation			653	86
Shares Paid for Tax Withholding for Share Based Compensation Market Price (in dollars per share)			$ 162.93	$ 127.05
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation			21,914	20,457
Shares Paid for Tax Withholding for Share Based Compensation Market Price (in dollars per share)			$ 216.8	$ 117.95
Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			2,958

Note 8 - Share-based Compensa_4

Note 8 - Share-based Compensation - Compensation Cost (Details) - Selling, General and Administrative Expenses [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based compensation	$ 1,539	$ 1,197	$ 4,787	$ 3,450
Common Stock [Member]
Share-based compensation	100	100	300	300
Employee and Nonemployee Stock Option [Member]
Share-based compensation	127	112	357	320
Restricted Stock Units (RSUs) [Member]
Share-based compensation	$ 1,312	$ 985	$ 4,130	$ 2,830

Note 8 - Share-based Compensa_5

Note 8 - Share-based Compensation - Summary of Stock Option Activity (Details) - Employee and Nonemployee Stock Option [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Outstanding, options (in shares) | shares	78,488
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 39.98
Granted, options (in shares) | shares	2,958
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 260.92
Exercised, options (in shares) | shares	(6,568)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 32.35
Outstanding, options (in shares) | shares	74,878
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 67.67
Outstanding, weighted average remaining life (Year)	5 years 2 months 1 day
Outstanding, intrinsic value | $	$ 18,669
Exercisable, options (in shares) | shares	67,952
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 56.36
Exercisable, weighted average remaining life (Year)	5 years 29 days
Exercisable, intrinsic value | $	$ 17,690
Vested and expected to vest, options (in shares) | shares	74,878
Vested and expected to vest, weighted average exercise price (in dollars per share) | $ / shares	$ 67.67
Vested and expected to vest, weighted average remaining life (Year)	5 years 2 months 1 day
Vested and expected to vest, intrinsic value | $	$ 18,669

Note 8 - Share-based Compensa_6

Note 8 - Share-based Compensation - Black-Scholes Option Pricing Model (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares
Expected volatility	39.70%
Risk-free interest rate	4.30%
Exercise price (in dollars per share)	$ 260.92
Expected term (Year)	6 years 3 months 18 days
Weighted-average grant date fair value (in dollars per share)	$ 121.61

Note 8 - Share-based Compensa_7

Note 8 - Share-based Compensation - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Outstanding, restricted stock units (in shares) | shares	95,693
Outstanding, weighted average award date fair value (in dollars per share) | $ / shares	$ 64.82
Awarded, restricted stock units (in shares) | shares	31,663
Awarded, weighted average award date fair value (in dollars per share) | $ / shares	$ 175.3
Shares vested, restricted stock units (in shares) | shares	(50,582)
Shares vested, weighted average award date fair value (in dollars per share) | $ / shares	$ 79.53
Shares forfeited, restricted stock units (in shares) | shares	(559)
Shares forfeited, weighted average award date fair value (in dollars per share) | $ / shares	$ 135.81
Outstanding, restricted stock units (in shares) | shares	76,215
Outstanding, weighted average award date fair value (in dollars per share) | $ / shares	$ 95.82

Note 9 - Inventories - Summary

Note 9 - Inventories - Summary of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Raw materials	$ 63,530	$ 53,539
Work in process	8,846	7,821
Finished goods	16,314	8,831
Total inventory	$ 88,690	$ 70,191

Note 10 - Property, Plant and_3

Note 10 - Property, Plant and Equipment - Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, plant, and equipment	$ 133,314	$ 119,322
Accumulated depreciation and amortization	(63,003)	(57,185)
Net property, plant and equipment	70,311	62,137
Land and Land Improvements [Member]
Property, plant, and equipment	5,850	4,849
Building and Building Improvements [Member]
Property, plant, and equipment	38,079	34,735
Leasehold Improvements [Member]
Property, plant, and equipment	9,418	8,226
Machinery and Equipment [Member]
Property, plant, and equipment	65,259	58,343
Furniture, Fixtures, and Computers [Member]
Property, plant, and equipment	7,375	6,324
Construction in Progress [Member]
Property, plant, and equipment	$ 7,333	$ 6,845

Note 11 - Leases - Right-of-Use

Note 11 - Leases - Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Total ROU assets
Operating lease ROU assets	$ 15,340	$ 13,437
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Total ROU assets
Finance lease ROU assets	$ 107	151
Total ROU assets	$ 15,447	13,588
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total lease liabilities - current
Operating lease liabilities - current	$ 3,919	3,162
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total lease liabilities - current
Finance lease liabilities - current	$ 60	60
Total lease liabilities - current	$ 3,979	3,222
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Total lease liabilities - long-term
Operating lease liabilities - long-term	$ 11,911	10,719
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Total lease liabilities - long-term
Finance lease liabilities - long-term	$ 50	96
Total lease liabilities - long-term	$ 11,961	$ 10,815

Note 11 - Leases - Lease Cost (

Note 11 - Leases - Lease Cost (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Lease Cost:
Operating cash flows from operating leases	$ 2,723	$ 2,197
Amortization of right of use assets	71	45
Financing cash flows from finance leases	58	47
Interest on lease liabilities	5	3
Operating lease cost	$ 2,776	$ 2,304
Finance (Year)	1 year 4 months 24 days	2 years 9 months 14 days
Variable lease cost	$ 241	$ 240
Operating (Year)	4 years 2 months 15 days	4 years 6 months 25 days
Short-term lease cost	$ 136	$ 38
Finance	2.11%	2.10%
Total lease cost	$ 3,229	$ 2,630
Operating	4.87%	3.42%

Note 11 - Leases - Aggregate Fu

Note 11 - Leases - Aggregate Future Lease Payments (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Remainder of 2024, operating	$ 1,046
Remainder of 2024, finance	63
2025, operating	3,844
2025, finance	40
2026, operating	3,377
2026, finance	10
2027, operating	2,961
2027, finance	0
2028, operating	1,855
2028, finance	0
Thereafter, operating	5,329
Thereafter, finance	0
Total lease payments, operating	18,412
Total lease payments, finance	113
Less: Interest, operating	(2,582)
Less: Interest, finance	(3)
Present value of lease liabilities, operating	15,830
Present value of lease liabilities, finance	$ 110

Note 12 - Income Per Share (Det

Note 12 - Income Per Share (Details Textual) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0	4,281	0	12,153

Note 12 - Income Per Share - We

Note 12 - Income Per Share - Weighted Average Number of Shares Used to Compute Net EPS (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Basic (in shares)	7,674	7,639	7,666	7,619
Weighted average common equivalent shares due to restricted stock, stock options and RSUs (in shares)	98	70	97	78
Diluted weighted average common shares outstanding (in shares)	7,772	7,709	7,763	7,697

Note 13 - Segment Data (Details

Note 13 - Segment Data (Details Textual)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Number of Operating Segments			1
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers			2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage	26.70%	30.30%	30.30%	24.70%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customer [Member]
Concentration Risk, Percentage	24%		12.40%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Geographic Distribution, Foreign [Member]
Concentration Risk, Percentage	14.70%	15.40%	17.10%	16.80%
Customer Concentration Risk [Member] | Long-Lived Assets [Member] | Geographic Distribution, Foreign [Member]
Concentration Risk, Percentage			18.40%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers			3	1	2
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage					16.50%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage			14.90%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk, Percentage			13.60%		12.20%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]
Concentration Risk, Percentage			11.60%

Note 13 - Segment Data - Net Sa

Note 13 - Segment Data - Net Sales by Market (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net sales	$ 145,165	$ 100,784	$ 360,351	$ 298,575
Percentage of concentration risk	100%	100%	100%	100%
Medical [Member]
Net sales	$ 132,623	$ 87,127	$ 318,079	$ 257,092
Percentage of concentration risk	91.40%	86.50%	88.30%	86.10%
industrial or Other [Member]
Net sales	$ 4,637	$ 4,902	$ 14,484	$ 15,834
Percentage of concentration risk	3.20%	4.90%	3.90%	5.30%
Aerospace & Defense [Member]
Net sales	$ 4,444	$ 4,377	$ 16,401	$ 12,828
Percentage of concentration risk	3.10%	4.30%	4.60%	4.30%
Automotive [Member]
Net sales	$ 3,461	$ 4,378	$ 11,387	$ 12,821
Percentage of concentration risk	2.30%	4.30%	3.20%	4.30%

Note 14 - Goodwill and Other _3

Note 14 - Goodwill and Other Intangible Assets (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Amortization of Intangible Assets	$ 2	$ 1	$ 4.2	$ 3.1

Note 14 - Goodwill and Other _4

Note 14 - Goodwill and Other Intangible Assets - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
December 31, 2023	$ 113,263
Foreign currency translation	177
September 30, 2024	204,732
Marble Medical, Inc [Member]
Acquired in Marble Medical business combination	2,564
AJR Enterprises, LLC [Member]
Acquired in Marble Medical business combination	41,710
Welch Fluorocarbon, Inc [Member]
Acquired in Marble Medical business combination	19,367
AQF [Member]
Acquired in Marble Medical business combination	$ 27,651

Note 14 - Goodwill and Other _5

Note 14 - Goodwill and Other Intangible Assets - Definite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Gross amount	$ 152,730
Accumulated amortization	(18,012)
Net balance	134,718	$ 64,116
Intellectual Property/ Tradename and Brand [Member]
Gross amount	25,931
Accumulated amortization	(2,085)
Net balance	$ 23,846
Intellectual Property/ Tradename and Brand [Member] | Weighted Average [Member]
Weighted-average amortization period (Year)	12 years
Noncompete Agreements [Member]
Gross amount	$ 6,791
Accumulated amortization	(1,971)
Net balance	$ 4,820
Noncompete Agreements [Member] | Weighted Average [Member]
Weighted-average amortization period (Year)	8 years 9 months 18 days
Customer Lists [Member]
Gross amount	$ 120,008
Accumulated amortization	(13,956)
Net balance	$ 106,052
Customer Lists [Member] | Weighted Average [Member]
Weighted-average amortization period (Year)	20 years

Note 14 - Goodwill and Other _6

Note 14 - Goodwill and Other Intangible Assets - Future Amortization of Intangible Assets (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Remainder of 2024	$ 2,177
2025	8,710
2026	8,707
2027	8,654
2028	8,551
2029	8,604
Thereafter	89,315
Total	$ 134,718

Note 15 - Other Long-term Lia_3

Note 15 - Other Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accrued contingent consideration (earn-out)	$ 4,751	$ 8,096
Present value of non-competition payments	5,387	6,586
Other	806	499
Other Liabilities, Noncurrent	$ 10,944	$ 15,181

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Effective Income Tax Rate Reconciliation, Percent	22.90%	17.30%	21%	20.70%

Note 17 - Debt (Details Textual

Note 17 - Debt (Details Textual) - USD ($)	Jun. 27, 2024	Sep. 30, 2024
Long-Term Debt		$ 212,000,000
Subsidiary Guarantors [Member] | Third Amended and Restated Credit Agreement [Member]
Debt Instrument, Face Amount	$ 275,000,000
Long-Term Debt		212,000,000
Letters of Credit Outstanding, Amount		$ 700,000
Debt Instrument, Interest Rate, Stated Percentage		6.50%
Subsidiary Guarantors [Member] | Third Amended and Restated Credit Agreement [Member] | Bloomberg Short-term Bank Yield Index Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.25%
Subsidiary Guarantors [Member] | Third Amended and Restated Credit Agreement [Member] | Bloomberg Short-term Bank Yield Index Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	2.25%
Subsidiary Guarantors [Member] | Third Amended and Restated Credit Agreement [Member] | Prime Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.25%
Subsidiary Guarantors [Member] | Third Amended and Restated Credit Agreement [Member] | Prime Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.25%
Subsidiary Guarantors [Member] | Third Amended and Restated Credit Agreement [Member] | Secured Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 150,000,000
Debt Instrument, Periodic Payment, Principal	3,125,000
Subsidiary Guarantors [Member] | Third Amended and Restated Credit Agreement [Member] | Secured Term Loan [Member]
Debt Instrument, Face Amount	$ 125,000,000

Note 17 - Debt - Long-term debt

Note 17 - Debt - Long-term debt (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Revolving credit facility	$ 212
Current portion	(12.5)	$ (4)
Long-term debt, excluding current portion	199.5	$ 28
Term Loan [Member]
Revolving credit facility	125
Revolving Credit Facility [Member] | Line of Credit [Member]
Revolving credit facility	$ 87

Note 17 - Debt - Schedule of Ma

Note 17 - Debt - Schedule of Maturity (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Remainder of 2024	$ 3,125
2025	12,500
2026	12,500
2027	12,500
2028	12,500
2029	158,875
Long-Term Debt	212,000
Revolving Credit Facility [Member] | Line of Credit [Member]
Remainder of 2024	0
2025	0
2026	0
2027	0
2028	0
2029	87,000
Long-Term Debt	87,000
Term Loan [Member]
Remainder of 2024	3,125
2025	12,500
2026	12,500
2027	12,500
2028	12,500
2029	71,875
Long-Term Debt	$ 125,000